FMP
Belite Bio, Inc
BLTE
NASDAQ
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.
56.9 USD
-7.13 (-12.53%)
Earnings
Dividends
We are unable to load the chart at this time.
Splits
We are unable to load the chart at this time.
From:
To:
Date
Revenue
Earnings
Estimated Earnings
Surprise
2025-03-17
0
-0.32
-0.3
6.67%
2024-11-12
0
-0.28
-0.3
-6.67%
2024-08-09
0
-0.31
-0.28
10.71%
2024-05-13
0
-0.27
-0.34
-20.59%
2024-03-11
0
-0.25
-0.36
-30.56%
2023-11-13
0
-0.4
-0.31
29.03%
2023-08-08
0
-0.26
-0.24
8.33%
2023-05-10
0
-0.33
-0.2
65.00%
2023-03-31
0
-10.44k
-0.22
4743955.95%
2022-09-30
0
-0.1
0
-
2022-08-10
0
-0.12
-0.23
-49.67%
2022-04-29
0
-0.26
0
-
2022-03-31
0
-0.05
0
-
2021-09-30
0
-0.26
0
-
2021-06-30
0
-0.25
0
-
2021-03-31
0
-0.25
0
-
2020-12-31
0
-0.21
0
-
2020-09-30
0
-0.21
0
-
2020-06-30
0
-0.12
0
-
2020-03-31
0
-0.12
0
-
